Literature DB >> 12112367

Chlorotoxin, a scorpion-derived peptide, specifically binds to gliomas and tumors of neuroectodermal origin.

Susan A Lyons1, Jeffrey O'Neal, Harald Sontheimer.   

Abstract

Highly migratory neuroectodermal cells share a common embryonic origin with cells of the central nervous system (CNS). They include enteric, parasympathetic, sympathoadrenal, and sensory neurons of the peripheral nervous system, Schwann cells, melanocytes, endocrine cells, and cells forming connective tissue of the face and neck. Because of their common embryologic origin, these cells and the tumors that derive from them can share genetic and antigenic phenotypes with gliomas, tumors derived from CNS glia. We recently discovered that chlorotoxin (ClTx), a 4-kD peptide purified from Leiurus quinquestriatus scorpion, is a highly specific marker for glioma cells in biopsy tissues (Soroceanu et al. Cancer Res 58:4871-4879, 1998) that can target tumors in animal models. We report on the specificity of ClTx as a marker for tumors of neuroectodermal origin that include peripheral neuroectodermal tumors (PNET) and gliomas. Specifically, we histochemically stained frozen and paraffin tissue sections of human biopsy tissues from 262 patients with a synthetically manufactured and biologically active ClTx bearing an N-terminal biotin. The vast majority (74 of 79) of primary human brain tumors investigated showed abundant binding of ClTx with greater than 90% ClTx-positive cells in each section. By comparison, 32 biopsies of uninvolved brain used for comparison were largely ClTx-negative, with only a few isolated reactive astrocytes showing some ClTx binding. However, as with gliomas, the vast majority of PNETs examined showed specific ClTx binding (31 of 34). These include medulloblastomas (4 of 4), neuroblastomas (6 of 7), ganglioneuromas (4 of 4), melanomas (7 of 7), adrenal pheochromocytomas (5 of 6), primitive PNET (1), small cell lung carcinoma (2 of 3), and Ewing's sarcoma (2 of 2). Under identical staining conditions, normal tissues from brain, skin, kidney, and lung were consistently negative for ClTx. These results suggest that chlorotoxin is a reliable and specific histopathological marker for tumors of neuroectodermal origin and that chlorotoxin derivatives with cytolytic activity may have therapeutic potential for these cancers. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12112367     DOI: 10.1002/glia.10083

Source DB:  PubMed          Journal:  Glia        ISSN: 0894-1491            Impact factor:   7.452


  91 in total

Review 1.  Unique biology of gliomas: challenges and opportunities.

Authors:  Stacey Watkins; Harald Sontheimer
Journal:  Trends Neurosci       Date:  2012-06-08       Impact factor: 13.837

2.  Chlorotoxin labeled magnetic nanovectors for targeted gene delivery to glioma.

Authors:  Forrest M Kievit; Omid Veiseh; Chen Fang; Narayan Bhattarai; Donghoon Lee; Richard G Ellenbogen; Miqin Zhang
Journal:  ACS Nano       Date:  2010-08-24       Impact factor: 15.881

3.  PEG-mediated synthesis of highly dispersive multifunctional superparamagnetic nanoparticles: their physicochemical properties and function in vivo.

Authors:  Conroy Sun; Kim Du; Chen Fang; Narayan Bhattarai; Omid Veiseh; Forrest Kievit; Zachary Stephen; Donghoon Lee; Richard G Ellenbogen; Buddy Ratner; Miqin Zhang
Journal:  ACS Nano       Date:  2010-04-27       Impact factor: 15.881

4.  Near Infrared Fluorescent Nanoplatform for Targeted Intraoperative Resection and Chemotherapeutic Treatment of Glioblastoma.

Authors:  Derek Reichel; Bien Sagong; James Teh; Yi Zhang; Shawn Wagner; Hongqiang Wang; Leland W K Chung; Pramod Butte; Keith L Black; John S Yu; J Manuel Perez
Journal:  ACS Nano       Date:  2020-06-23       Impact factor: 15.881

5.  Polymalic acid chlorotoxin nanoconjugate for near-infrared fluorescence guided resection of glioblastoma multiforme.

Authors:  Rameshwar Patil; Anna Galstyan; Tao Sun; Ekaterina S Shatalova; Pramod Butte; Adam N Mamelak; Christine Carico; David S Kittle; Zachary B Grodzinski; Antonella Chiechi; Hui Ding; Keith L Black; Julia Y Ljubimova; Eggehard Holler
Journal:  Biomaterials       Date:  2019-03-23       Impact factor: 12.479

6.  Tumor-targeted drug delivery and MRI contrast enhancement by chlorotoxin-conjugated iron oxide nanoparticles.

Authors:  Conroy Sun; Chen Fang; Zachary Stephen; Omid Veiseh; Stacey Hansen; Donghoon Lee; Richard G Ellenbogen; Jim Olson; Miqin Zhang
Journal:  Nanomedicine (Lond)       Date:  2008-08       Impact factor: 5.307

Review 7.  Nanoneuromedicines for degenerative, inflammatory, and infectious nervous system diseases.

Authors:  Howard E Gendelman; Vellareddy Anantharam; Tatiana Bronich; Shivani Ghaisas; Huajun Jin; Anumantha G Kanthasamy; Xinming Liu; JoEllyn McMillan; R Lee Mosley; Balaji Narasimhan; Surya K Mallapragada
Journal:  Nanomedicine       Date:  2015-01-31       Impact factor: 5.307

Review 8.  Navigating CAR-T cells through the solid-tumour microenvironment.

Authors:  Andrew J Hou; Laurence C Chen; Yvonne Y Chen
Journal:  Nat Rev Drug Discov       Date:  2021-05-10       Impact factor: 84.694

9.  Annexin A2 is a molecular target for TM601, a peptide with tumor-targeting and anti-angiogenic effects.

Authors:  Kamala Kesavan; Judson Ratliff; Eric W Johnson; William Dahlberg; John M Asara; Preeti Misra; John V Frangioni; Douglas B Jacoby
Journal:  J Biol Chem       Date:  2009-12-15       Impact factor: 5.157

10.  A ligand-mediated nanovector for targeted gene delivery and transfection in cancer cells.

Authors:  Omid Veiseh; Forrest M Kievit; Jonathan W Gunn; Buddy D Ratner; Miqin Zhang
Journal:  Biomaterials       Date:  2008-11-05       Impact factor: 12.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.